US20220057404A1 - Methods of detecting and reducing cancer cell central nervous system colonization - Google Patents
Methods of detecting and reducing cancer cell central nervous system colonization Download PDFInfo
- Publication number
- US20220057404A1 US20220057404A1 US17/224,431 US202117224431A US2022057404A1 US 20220057404 A1 US20220057404 A1 US 20220057404A1 US 202117224431 A US202117224431 A US 202117224431A US 2022057404 A1 US2022057404 A1 US 2022057404A1
- Authority
- US
- United States
- Prior art keywords
- pcdh9
- leukemia
- cns
- subject
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003169 central nervous system Anatomy 0.000 title claims abstract description 179
- 238000000034 method Methods 0.000 title claims abstract description 45
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 41
- 201000011510 cancer Diseases 0.000 title claims abstract description 39
- 102100034957 Protocadherin-9 Human genes 0.000 claims description 194
- 101710141455 Protocadherin-9 Proteins 0.000 claims description 194
- 208000032839 leukemia Diseases 0.000 claims description 132
- 230000014509 gene expression Effects 0.000 claims description 93
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 48
- 239000003112 inhibitor Substances 0.000 claims description 32
- 210000004369 blood Anatomy 0.000 claims description 23
- 239000008280 blood Substances 0.000 claims description 23
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 22
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 22
- 238000002560 therapeutic procedure Methods 0.000 claims description 20
- 238000002512 chemotherapy Methods 0.000 claims description 19
- 206010025323 Lymphomas Diseases 0.000 claims description 18
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 17
- 206010062489 Leukaemia recurrent Diseases 0.000 claims description 10
- 230000002441 reversible effect Effects 0.000 claims description 7
- 230000005855 radiation Effects 0.000 claims description 6
- 238000009121 systemic therapy Methods 0.000 claims description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 description 169
- 208000025324 B-cell acute lymphoblastic leukemia Diseases 0.000 description 74
- 230000007170 pathology Effects 0.000 description 50
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 43
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 42
- 108090000623 proteins and genes Proteins 0.000 description 40
- 238000011282 treatment Methods 0.000 description 40
- 241000699670 Mus sp. Species 0.000 description 37
- 239000000523 sample Substances 0.000 description 33
- 230000009885 systemic effect Effects 0.000 description 25
- 230000002489 hematologic effect Effects 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 19
- 238000003197 gene knockdown Methods 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 15
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 14
- 108091027967 Small hairpin RNA Proteins 0.000 description 14
- 229960002448 dasatinib Drugs 0.000 description 14
- 238000010172 mouse model Methods 0.000 description 14
- 239000004055 small Interfering RNA Substances 0.000 description 14
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 13
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 238000012546 transfer Methods 0.000 description 10
- 108020004999 messenger RNA Proteins 0.000 description 9
- 210000004214 philadelphia chromosome Anatomy 0.000 description 9
- 230000004083 survival effect Effects 0.000 description 9
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 230000007774 longterm Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 206010033799 Paralysis Diseases 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 201000010039 central nervous system leukemia Diseases 0.000 description 6
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 5
- 108091000080 Phosphotransferase Proteins 0.000 description 5
- 108020004459 Small interfering RNA Proteins 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229960002411 imatinib Drugs 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000007913 intrathecal administration Methods 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 102000020233 phosphotransferase Human genes 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 238000011740 C57BL/6 mouse Methods 0.000 description 4
- 108091033409 CRISPR Proteins 0.000 description 4
- 108010023356 Nonmuscle Myosin Type IIA Proteins 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 230000000719 anti-leukaemic effect Effects 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 208000018805 childhood acute lymphoblastic leukemia Diseases 0.000 description 4
- 230000005014 ectopic expression Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 description 3
- 206010029350 Neurotoxicity Diseases 0.000 description 3
- 238000003559 RNA-seq method Methods 0.000 description 3
- 206010044221 Toxic encephalopathy Diseases 0.000 description 3
- 230000001174 ascending effect Effects 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000011633 childhood acute lymphocytic leukemia Diseases 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000002939 deleterious effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
- 229960003957 dexamethasone Drugs 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229960003685 imatinib mesylate Drugs 0.000 description 3
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000007918 intramuscular administration Methods 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000007135 neurotoxicity Effects 0.000 description 3
- 231100000228 neurotoxicity Toxicity 0.000 description 3
- 230000001177 retroviral effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 206010000830 Acute leukaemia Diseases 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 238000010354 CRISPR gene editing Methods 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000735376 Homo sapiens Protocadherin-8 Proteins 0.000 description 2
- 208000035561 Leukaemic infiltration brain Diseases 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 206010027926 Monoplegia Diseases 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 102100034958 Protocadherin-8 Human genes 0.000 description 2
- 108700040559 Protocadherins Proteins 0.000 description 2
- 238000010240 RT-PCR analysis Methods 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000011394 anticancer treatment Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000008499 blood brain barrier function Effects 0.000 description 2
- 210000001218 blood-brain barrier Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000005829 chemical entities Chemical class 0.000 description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 238000011461 current therapy Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 208000010726 hind limb paralysis Diseases 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 201000003723 learning disability Diseases 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-methyl-PhOH Natural products CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- QWVGKYWNOKOFNN-UHFFFAOYSA-N o-cresol Chemical compound CC1=CC=CC=C1O QWVGKYWNOKOFNN-UHFFFAOYSA-N 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 208000010713 partial hind limb paralysis Diseases 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 208000002491 severe combined immunodeficiency Diseases 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 230000005945 translocation Effects 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- 108020005544 Antisense RNA Proteins 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 229940118364 Bcr-Abl inhibitor Drugs 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- 208000004860 Blast Crisis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 206010010099 Combined immunodeficiency Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 108010013985 adhesion receptor Proteins 0.000 description 1
- 102000019997 adhesion receptor Human genes 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 102000004441 bcr-abl Fusion Proteins Human genes 0.000 description 1
- 108010056708 bcr-abl Fusion Proteins Proteins 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012829 chemotherapy agent Substances 0.000 description 1
- 238000009104 chemotherapy regimen Methods 0.000 description 1
- 201000002797 childhood leukemia Diseases 0.000 description 1
- 238000002983 circular dichroism Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002559 cytogenic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- -1 dasatinib TKI Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 108010021843 fluorescent protein 583 Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4727—Calcium binding proteins, e.g. calmodulin
Definitions
- ALL Acute lymphoblastic Leukemia
- CNS Central Nervous System
- the CNS acts as a ‘sanctuary’ site due to the presence of the blood brain barrier, which shields hematological cancer cells (such as leukemia cells and lymphoma cells) from treatments including tyrosine kinase inhibitors (TKIs) and chemotherapy (Aragon-Ching, J.
- TKIs tyrosine kinase inhibitors
- interventions that prevent or reverse hematological cancer cell (including leukemia and/or lymphoma cell) colonization of the CNS are novel tools to achieve full remission and improve long-term survival while reducing the severe side effects of CNS-directed treatments.
- One embodiment of the present invention is a method of treating cancer comprising administering to a subject in need thereof, a PCDH9 inhibitor.
- the cancer is leukemia or lymphoma.
- the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
- Another embodiment of the present invention is a method to identify a subject at risk for leukemia cell colonization of the central nervous system (CNS) in a subject having leukemia, the method comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; and (c) identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control.
- CNS central nervous system
- Still another embodiment of the present invention is a method to reduce leukemia relapse in a subject, comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; (c) identifying the subject as at risk for leukemia relapse when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and (d) administering a PCDH9 inhibitor to the subject at risk.
- Another embodiment method to inhibit or reverse leukemia cell colonization of the CNS in a subject comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; (c) identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and (d) administering a PCDH9 inhibitor to the subject.
- the PCDH9 inhibitor is selected from the group consisting of an antibody, an antisense molecule, an siRNA molecule, an shRNA molecule, a receptor antagonist, a chemical entity, a nucleotide, a peptide, and a protein.
- the PCDH9 inhibitor is an PCDH9 antibody.
- the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
- a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
- FIGS. 1A and 1B Differential phenotype of systemic B-cell acute lymphoblastic leukemia (B-ALL) and CNS B-ALL after in vivo transfer. 5 ⁇ 10 4 systemic B-ALL cells or CNS B-ALL cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology.
- FIG. 1A Quantification of spleen weight at the time of death of recipient mice transferred with either CNS or systemic B-ALL cells. Black line indicates normal spleen weight.
- FIG. 1B Quantification of CNS pathology in recipient mice transferred with CNS or systemic B-ALL cells.
- FIG. 2 PCDH9 is expressed in CNS leukemia cells but not systemic leukemia cells. Western blot analysis showing protein expression of PCDH9 in CNS B-ALL cells and lack of protein expression in systemic B-ALL cells.
- FIG. 3 shRNA-mediated depletion of PCDH9 in CNS leukemia cells. Western blot analysis showing PCDH9 protein levels in CNS B-ALL cells transduced with either control shRNA or PCDH9 specific shRNA.
- FIGS. 4A and 4B PCDH9 depletion in B-ALL cells greatly reduces the incidence and severity of CNS pathology.
- 5 ⁇ 10 4 control or PCDH9 KD (knock-down) CNS B-ALL cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology (as described in FIG. 1 ).
- FIG. 4B Quantification of severity of CNS pathology in recipient mice (p ⁇ 0.0001). Data are pooled from 2 experiments with cohorts of 5 mice/group/experiment; error bars are SEM.
- FIG. 5 PCDH9 is expressed in CNS B-ALL and in NALM-6 leukemia cells, but not systemic B-ALL cells.
- Western blot analysis showing protein expression of PCDH9 in CNS B-ALL and NALM-6 cells and lack of PCDH9 expression in systemic B-ALL cells.
- FIG. 6 NALM-6 leukemia cells cause CNS pathology. 10 6 NALM-6 cells were transferred into severe combined immunodeficiency (SCID) recipient mice and scored daily for signs of leukemia and CNS pathology (as described in the text and FIG. 1 ). Quantification of severity of CNS pathology in recipient mice is shown.
- SCID severe combined immunodeficiency
- FIGS. 7A and 7B PCDH9 KO (knock-out) in NALM-6 human leukemia cells greatly reduces the incidence and severity of CNS pathology. 5 ⁇ 10 4 control or PCDH9 KO NALM-6 cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology.
- FIG. 7B Quantification of severity of CNS pathology in recipient mice (p ⁇ 0.0001). Data are pooled from 3 experiments with cohorts of 4-5 mice/group/experiment; error bars are SEM.
- FIG. 9 shows a schematic for the setup for the long-term CNS colonization experiments discussed in the example section.
- Acute lymphoblastic Leukemia is the most common childhood cancer.
- Current therapies achieve high remission rates, but a significant number of patients relapse, often with Central Nervous System (CNS) involvement.
- CNS-directed treatments reduce CNS relapses but do not eliminate them.
- CNS-directed treatments such as cranial irradiation, intrathecal administration of chemotherapy, or high dose chemotherapy have been used to reduce CNS relapses. While the relapse rate has been significantly lowered, particularly with some high-intensity CNS-specific treatments, it has not been completely eliminated.
- short- and long-term side-effects of CNS-directed treatments such as acute neurotoxicity, brain cancer, cognitive impairment and learning disabilities, can be very severe particularly in children.
- targets that enable leukemia cell colonization of the CNS have been identified by comparing leukemia cells that colonize the CNS versus leukemia cells that do not.
- This analysis identified Protocadherin-9 (PCDH9) as an ectopically expressed protein in CNS-colonizing leukemia cells. Based on this data, ectopic expression of PCDH9 can enable leukemia cells to colonize the CNS and give rise to CNS pathology and relapses.
- PCDH9 Protocadherin-9
- ectopic expression of PCDH9 can enable leukemia cells to colonize the CNS and give rise to CNS pathology and relapses.
- PCDH9 is a new diagnostic target that can establish the risk for CNS colonization in leukemia patients. This allows more effective stratification of CNS treatments, thereby reducing the use and intensity of deleterious CNS-directed therapies in lower risk patients including pediatric patients and thus improving their quality of life.
- hematological cancer cells such as leukemia cells or lymphoma cells
- these cells can establish a niche, escape systemic anti-cancer treatments, and eventually give rise to CNS relapses.
- the mechanisms of leukemia cell entry and colonization of the CNS are mostly unknown.
- B-ALL pre-B cell ALL
- factors that allow leukemia cells to enter and colonize the CNS have been determined.
- the gene expression profile of two similarly derived mouse B-ALL cell lines that have very different CNS colonization phenotypes were compared.
- the first ALL cell line has a typical ‘systemic’ phenotype of bone marrow and spleen involvement, while the second B-ALL cell line rapidly disseminates to the CNS and gives rise to CNS pathology (ascending paralysis of the recipient mice) ( FIG. 1 —pathology scoring).
- RNA sequencing analysis revealed that the most differentially expressed gene was PCDH9.
- PCDH9 is a transmembrane adhesion receptor of the protocadherin family, which is known to mediate calcium-dependent cell adhesion in neuronal tissues (Strehl, S., Glatt, K., Liu, Q. M., Glatt, H. & Lalander, M. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14 . Genomics 53, 81-89 (1998)).
- PCDH9 was virtually absent in the B-ALL line that exhibited a systemic phenotype, and was highly expressed (>27-fold) in the B-ALL line with the CNS colonization phenotype by both mRNA and Western Blot analysis (Table 1, FIG. 2 ).
- PCDH9 is not expressed in normal leukocytes, but gene profiling of leukemia patient samples available in public databases shows that PCDH9 is ectopically expressed in various human leukemia samples.
- PCDH9 upregulation is also a poor prognostic factor in ALL (Silveira, V. S. et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia & lymphoma 54, 310-314 (2013)).
- PCDH9 depletion in leukemia cells greatly reduces their ability to give rise to CNS pathology ( FIG. 4 ). Based on these data, ectopic expression of PCDH9 in leukemia cells is expected to enable leukemia cells to colonize the CNS and cause CNS pathology and relapses. Both the mouse ALL model just described and a human ALL xenograft model that also gives rise to CNS pathology in recipient mice can be used.
- PCDH9 The role of PCDH9 in allowing leukemia cells to enter and colonize the CNS, and give rise to CNS pathology and relapse is demonstrated herein. Furthermore, the results provide target validation for PCDH9 as a novel point of therapeutic intervention to inhibit leukemia cell colonization of the CNS and prevent relapses, including as part of combination therapies. Given the serious side-effects of CNS-directed therapies in children, inhibiting CNS colonization of leukemia cells is a valuable tool to improve current therapies by decreasing relapses following TKI and chemotherapy while also reducing the need or intensity of CNS-directed therapies.
- Leukemia as well as lymphoma cell colonization of the CNS can be particularly problematic since the CNS acts as ‘sanctuary’ site that protects leukemia or lymphoma cells from systemic treatments including chemotherapy and TKIs. This is mainly due to the reduced permeability of these drugs through the blood-brain barrier (Aragon-Ching, J. B. & Zujewski, J. A. CNS metastasis: an old problem in a new guise. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 1644-1647 (2007); Wolff, N.C., Richardson, J. A., Egorin, M. & Ilaria, R. L., Jr.
- the CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101, 5010-5013 (2003)).
- therapeutics that inhibit leukemia and/or lymphoma cell colonization of the CNS can be used, in combination with systemic TKIs and/or chemotherapy, to more completely eradicate leukemia, to prevent relapses, and thereby increase long-term survival (typically defined as longer than 5 years from diagnosis in the case of ALL).
- reducing the need, frequency and intensity of treatments such as intrathecal chemotherapy can significantly reduce the deleterious side-effects of these therapies especially in children.
- PCDH9 as a novel target for prevention of leukemia CNS relapses: Relatively little is known about PCDH9. It belongs to the protocadherin family, a group of transmembrane proteins that mediate Ca′-dependent homotypic cell adhesion. PCDH9 is predominantly expressed in neuronal tissues and not normally expressed in leukocytes (Strehl, S., Glatt, K., Liu, Q. M., Glatt, H. & Lalander, M. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14 . Genomics 53, 81-89 (1998)).
- PCDH9 in human leukemia cells has been demonstrated by expression profiling, and includes but is not limited to human ALL. Furthermore, PCDH9 expression is a poor prognostic factor in ALL (Silveira, V. S. et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia & lymphoma 54, 310-314 (2013)). Ectopic expression of PCDH9 in leukemia cells is believed to allow them to adhere and interact with neuronal and/or glial cells enabling the leukemia cells to establish a niche in the CNS.
- PCDH9 expression in leukemia cells is a factor that enables leukemia cells to colonize the CNS which allows for staining leukemia cells from a patient's blood sample for PCDH9 expression. This is a novel and greatly improved method to establish the risk for CNS colonization in leukemia patients. This enables more effective treatment stratification, thereby reducing the need and intensity of harmful CNS-directed therapies in lower risk patients.
- a mouse ALL model and a human ALL xenograft model that both give rise to CNS pathology are used to compare the ability of control ALL cells and PCDH9-depleted ALL cells to colonize the CNS and induce CNS pathology.
- PCDH9 expression in leukemia cells enables their establishment in the CNS.
- CNS B-ALL cells in a mouse ALL transfer model, the ability of control shRNA and PCDH9 shRNA (PCDH9 KD) B-ALL cells to infiltrate the CNS and give rise to CNS pathology by time-course analysis is compared.
- PCDH9 KD PCDH9 shRNA
- NALM-6 human leukemia cell line NALM-6
- knock-out (KO) of PCDH9 is shown to prevent CNS pathology by the human leukemia cells.
- Two mouse Bcr-Abl+Arf ⁇ / ⁇ B-ALL cell lines were derived by transducing bone marrow cells from Arf ⁇ / ⁇ (a tumor suppressor) C57BL/6 mice with p185Bcr-Abl and co-expressing either a GFP or luciferase as a marker (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011); Williams, R. T., Roussel, M. F. & Sherr, C. J.
- the luciferase-expressing B-ALL cell line gives rise to a typical ‘systemic’ phenotype of bone marrow and spleen involvement, while the GFP-expressing B-ALL cell line infiltrates the CNS and gives rise to CNS pathology (paralysis of the recipient mice) in addition to systemic dissemination ( FIG. 1 ).
- NALM-6 a xenograft model with the human pre-B cell ALL cell line NALM-6, which carries a (5; 12) translocation was used.
- NALM-6 cells reliably engraft in SCID mice and have been used to test anti-leukemia experimental therapies in vivo (Jacoby, E., Chien, C. D. & Fry, T. J. Murine models of acute leukemia: important tools in current pediatric leukemia research. Frontiers in oncology 4, 95 (2014)).
- NALM-6 cells colonize the CNS at high frequency leading to CNS pathology in the recipient mice similarly to the mouse B-ALL model (Gunther, R. et al.
- PCDH9 Differential expression of PCDH9 in systemic vs. CNS leukemia cells.
- RNA sequencing analysis was done to investigate differences in the expression profile between these B-ALL cell lines. Analysis revealed that the most differentially expressed gene was PCDH9, which was virtually absent from the systemic B-ALL cells and highly expressed in the CNS B-ALL cells (>27-fold based on the DSeq2 software analysis which normalizes fold changes based on expression levels and variance) (Table 1 and FIG. 2 ).
- PCDH9 protein expression in NALM-6 ALL cells FIG. 5 was also confirmed.
- PCDH9 expression was knocked-down (KD) using an shRNA-mediated approach ( FIG. 3 ).
- CNS B-ALL cells were transduced with control or PCDH9 inhibitory shRNA using retroviral vectors (pSiren-retroQ from Clontech), employing techniques similar to those used in other studies (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016); Jacobelli, J., Bennett, F.
- PCDH9 depletion significantly reduces CNS pathology caused by B-ALL transfer In experiments the in vivo effects of transferring CNS B-ALL cells transduced with either control shRNA or PCDH9 shRNA was compared. Even though, in the absence of anti-leukemia treatments, mice transferred with control or PCDH9 KD B-ALL cells eventually succumbed to the leukemia, the data showed that PCDH9 depletion in leukemia cells strongly reduced their ability to cause CNS pathology in the recipient mice ( FIG. 4 ).
- PCDH9 KO human NALM-6 leukemia cells were transferred into SCID mice and leukemia progression and CNS pathology was monitored over time. These data showed that PCDH9 KO significantly reduced and almost eliminated the ability of NALM-6 cells to cause CNS pathology ( FIG. 7 ). Overall, these data support that PCDH9 expression enables leukemia cells to colonize the CNS and cause CNS pathology.
- PCDH9 expression was analyzed from publicly available microarray gene expression data from a clinical study of ALL patients. Comparing patients with or without CNS relapse suggests that PCDH9 expression is significantly higher in the patients with CNS relapse ( FIG. 8 ).
- PCDH9 By validating PCDH9 as a target in leukemia, new therapeutics to prevent or reverse leukemia colonization of the CNS ‘sanctuary’ site provide new treatment options for leukemia. Identifying PCDH9 as a protein that enables leukemia cells to colonize the CNS is used to develop new diagnostics to establish the risk for CNS dissemination in leukemia patients and more effectively stratify treatment.
- One embodiment of the present invention is a method of treating cancer comprising administering to a subject in need thereof, a PCDH9 inhibitor.
- the cancer is a hematological cancer including but not limited to leukemia and/or lymphoma.
- the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
- ALL Acute Lymphoblastic Leukemia
- AML Acute Myeloid Leukemia
- the subject has been diagnosed as having cancer.
- the cancer is a hematological cancer.
- the cancer is a hematological cancer including but not limited to leukemia and/or lymphoma.
- the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
- ALL Acute Lymphoblastic Leukemia
- AML Acute Myeloid Leukemia
- the subject has been diagnosed as having cancer.
- the cancer is a hematological cancer.
- One embodiment of the present invention is a method to identify a subject at risk for hematological cancer cell colonization of the central nervous system (CNS) in a subject having been diagnosed as having the hematological cancer.
- the method comprising obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; and identifying the subject as at risk for hematological cancer cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control.
- the hematological cancer is leukemia or lymphoma.
- Still another embodiment of the present invention is a method to reduce hematological cancer relapse in a subject.
- the method comprises obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; identifying the subject as at risk for hematological cancer relapse when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and administering a PCDH9 inhibitor to the subject at risk.
- the hematological cancer is leukemia or lymphoma.
- Another embodiment of the present invention is the use of a PCDH9 inhibitor to reduce hematological cancer relapse in as subject.
- Another embodiment of the present invention is a method to inhibit or reverse hematological cancer cell colonization of the CNS in a subject.
- the method comprises obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; identifying the subject as at risk for hematological cancer cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCDH9 from a control; and administering a PCDH9 inhibitor to the subject.
- the hematological cancer is leukemia or lymphoma.
- Another embodiment of the present invention is the use of a PCDH9 inhibitor to inhibit or reduce hematological cancer cell colonization of the CNS in a subject.
- a patient or subject sample can include any bodily fluid or tissue from a patient that may contain the RNA or protein encoded by the genes contemplated here.
- the term “sample” or “patient sample” or “subject sample” can be used generally to refer to a sample of any type which contains products that are to be evaluated by the present method, including but not limited to, a sample of isolated cells, a tissue sample and/or a bodily fluid sample.
- a sample of isolated cells is a specimen of cells, typically in suspension or separated from connective tissue which may have connected the cells within a tissue in vivo, which have been collected from an organ, tissue or fluid by any suitable method which results in the collection of a suitable number of cells for evaluation by the method of the present invention.
- the sample can comprise blood.
- the sample can comprise whole blood, Peripheral Blood Mononuclear Cells (PBMCs), leukocytes, monocytes, lymphocytes, basophils, or eosinophils.
- PBMCs Peripheral Blood Mononuclear Cells
- the blood sample comprises leukemia cells.
- the leukemia cells can be separated out from other cells and components in a blood sample.
- the PCDH9 inhibitor can be selected from an antibody, an antisense molecule, an siRNA molecule, an shRNA molecule, a receptor antagonist, a chemical entity, a nucleotide, a peptide, and a protein.
- the PCDH9 inhibitor is a PCDH9 antibody.
- the term “expression”, when used in connection with detecting the expression of a gene, can refer to detecting transcription of the gene (i.e., detecting mRNA levels) and/or to detecting translation of the gene (detecting the protein produced).
- To detect expression of a gene refers to the act of actively determining whether a gene is expressed or not. This can include determining whether the gene expression is upregulated (or increased) as compared to a control, downregulated as compared to a control, or unchanged as compared to a control or increased or decreased as compared to a reference or control level.
- the step of detecting or determining expression does not require that expression of the gene actually is upregulated or downregulated or increased or decreased, but rather, can also include detecting or determining that the expression of the gene has not changed (i.e., detecting no expression of the gene or no change in expression of the gene).
- RNA expression is measured by any of a variety of known methods in the art.
- methods include but are not limited to: extraction of cellular mRNA and Northern blotting using labeled probes that hybridize to transcripts encoding all or part of the gene; amplification of mRNA using gene-specific primers, polymerase chain reaction (PCR), and reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative PCR, and/or RNA Ampliseq, followed by quantitative detection of the product by any of a variety of means; multiplexed quantitative PCR enrichment of cDNA amplicons, followed by conversion of amplicons to sequence libraries and Next-generation based sequencing of libraries to generate digital count expression data; extraction of total RNA from the cells, which is then labeled and used to probe cDNAs or oligonucleotides encoding the gene on any of a variety of surfaces; in situ hybridization; and detection of a reporter gene.
- Methods to measure protein expression levels generally include, but are not limited to: mass spectrometry, Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (MA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, microcytometry, microarray, microscopy, fluorescence activated cell sorting (FACS), and flow cytometry, as well as assays based on a property of the protein including but not limited to enzymatic activity or interaction with other protein partners.
- mass spectrometry Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (MA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohisto
- Binding assays are also well known in the art.
- a BIAcore machine can be used to determine the binding constant of a complex between two proteins.
- the dissociation constant for the complex can be determined by monitoring changes in the refractive index with respect to time as buffer is passed over the chip (O'Shannessy et al., 1993 , Anal. Biochem. 212:457; Schuster et al., 1993, Nature 365:343).
- suitable assays for measuring the binding of one protein to another include, for example, immunoassays such as enzyme linked immunoabsorbent assays (ELISA) and radioimmunoassays (MA); or determination of binding by monitoring the change in the spectroscopic or optical properties of the proteins through fluorescence, UV absorption, circular dichroism, or nuclear magnetic resonance (NMR).
- immunoassays such as enzyme linked immunoabsorbent assays (ELISA) and radioimmunoassays (MA); or determination of binding by monitoring the change in the spectroscopic or optical properties of the proteins through fluorescence, UV absorption, circular dichroism, or nuclear magnetic resonance (NMR).
- the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 is higher than the expression level of PCDH9 from a control.
- the expression can be at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, higher than the expression level from the control.
- the expression level can be at least about a 2 fold, at least about a 3 fold, at least about a 4 fold, at least about a 5 fold, at least about a 10-fold, at least about a 20 fold, at least about a 25 fold, at least about a 30 fold, at least about a 40 fold or at least about a 50 fold amount higher than the expression level from the control.
- reference to a reference or control means a subject who is a relevant reference or control to the subject being evaluated by the methods of the present invention.
- a relevant reference or control includes but is not limited to a subject or group of subjects having a hematological cancer such as leukemia or lymphoma, but have not relapsed over a determined time period.
- the reference or control expression level such as the level used to determine the threshold level, used in the comparison of the methods of the present invention can be determined from one or more relevant reference or control subjects.
- a therapeutically effective amount of a PCDH9 inhibitor or a composition comprising a PCDH9 inhibitor that is administered to a subject comprises an amount that is capable of inhibiting expression and/or activity of PCDH9 (mRNA and/or protein) without being toxic to the subject.
- An amount that is toxic to a subject comprises any amount that causes damage to the structure or function of a subject (i.e., poisonous).
- the PCDH9 inhibitor can be used in combination with current ALL therapies. This approach is particularly valuable in reducing the need, duration, or intensity of CNS-directed therapies (intrathecal chemotherapy or cranial irradiation) which have deleterious side-effects, particularly in children.
- the invention also provides for a kit for determining expression level of PCDH9.
- the kit can comprise one or more components selected from an antibody, an antisense RNA molecule, and a molecular probe or tag, wherein in the component can detect the expression of PCDH9.
- the composition as well as the kits of the present invention can comprise a pharmaceutically acceptable excipient.
- the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor can be administered with a pharmaceutically acceptable carrier, which includes pharmaceutically acceptable excipients and/or delivery vehicles, for delivering the agent to a subject (e.g., a liposome delivery vehicle).
- a pharmaceutically acceptable carrier refers to any substance suitable for delivering a therapeutic composition useful in the method of the present invention to a suitable in vivo or ex vivo site.
- Preferred pharmaceutically acceptable carriers are capable of maintaining the composition of the present invention in a form that, upon arrival of the composition to a target cell, the composition is capable of entering the cell and inhibiting PCDH9 (mRNA and/or protein) in the cell.
- PCDH9 is a surface molecule
- an anti-PCDH9 antibody can also inhibit PCDH9 on the surface of the cells without having to enter to the cells.
- Suitable excipients of the present invention include excipients or formularies that transport or help transport, but do not specifically target a nucleic acid molecule to a cell (also referred to herein as non-targeting carriers).
- Examples of pharmaceutically acceptable excipients include, but are not limited to water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters, glycols and combinations thereof.
- Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.
- Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer.
- Auxiliary substances can also include preservatives, such as thimerosal, m- or o-cresol, formalin and benzol alcohol.
- Compositions of the present invention can be sterilized by conventional methods and/or lyophilized.
- a PCDH9 inhibitor or composition comprising a PCDH9 inhibitor can be systemic, mucosal and/or proximal to the location of the target site (e.g., near a site of a tumor). Suitable routes of administration will be apparent to those of skill in the art, depending on the type of cancer to be prevented or treated and/or the target cell population or tissue.
- Various acceptable methods of administration include, but are not limited to, intravenous administration, intraperitoneal administration, intramuscular administration, intranodal administration, intracoronary administration, intraarterial administration (e.g., into a carotid artery), subcutaneous administration, transdermal delivery, intratracheal administration, intraarticular administration, intraventricular administration, inhalation (e.g., aerosol), intracranial, intraspinal, intraocular, aural, intranasal, oral, pulmonary administration, impregnation of a catheter, and direct injection into a tissue.
- routes of administration include: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal, intramuscular, transdermal, inhaled, intranasal, oral, intraocular, intraarticular, intracranial, and intraspinal.
- Parenteral delivery can include intradermal, intramuscular, intraperitoneal, intrapleural, intrapulmonary, intravenous, subcutaneous, atrial catheter and venal catheter routes.
- Aural delivery can include ear drops
- intranasal delivery can include nose drops or intranasal injection
- intraocular delivery can include eye drops.
- Aerosol (inhalation) delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992).
- one or more additional therapeutic agents or therapeutic protocols are administered or performed sequentially and/or concurrently with the administration of the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor, e.g., administration of chemotherapy, administration of radiation therapy, administration of a tyrosine kinase inhibitor (TKI), administration of an immunotherapy composition or immunotherapy including include the additional administration of other agents, such as cytokines, antibodies, or other agents.
- a PCDH9 inhibitor e.g., administration of chemotherapy, administration of radiation therapy, administration of a tyrosine kinase inhibitor (TKI)
- administration of an immunotherapy composition or immunotherapy including include the additional administration of other agents, such as cytokines, antibodies, or other agents.
- one or more therapies for cancer can be administered or performed prior to, concurrently with, or after the administration of the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor.
- one or more therapies can be administered or performed in an alternating manner.
- the subject can be any animal subject, and particularly, in any vertebrate mammal, including, but not limited to, primates, rodents, livestock or domestic pets.
- Preferred mammals for the methods of the present invention are humans.
- PCDH9-deficient leukemia cells Using a CNS B-ALL cell line, the ability of PCDH9-deficient leukemia cells to colonize the CNS in vivo is determined.
- 2 ⁇ 10 7 differentially fluorescently-labeled control and PCDH9 KD B-ALL cells, which express the congenic marker CD45.2 are intravenously (I. V.) co-transferred at a 1:1 ratio into CD45.1+C57BL/6 recipient mice.
- B-ALL cells For long-term assays (every 3 days for up to 3 weeks) 5 ⁇ 10 4 control or PCDH9 KD B-ALL cells are transferred into separate cohorts of CD45.1+recipient mice then, every 3 days, 2 randomly selected surviving mice from each cohort are euthanized for analysis ( FIG. 9 ). By transferring 2 ⁇ 10 7 B-ALL cells, B-ALL cells infiltrating the CNS 24 hours post-transfer are detected and with 5 ⁇ 10 4 transferred B-ALL cells, disease progression over 2-3 weeks (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J.
- Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016)) is monitored. Mice given 5 ⁇ 10 4 transferred control B-ALL typically succumb to the leukemia within 21 days (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016)).
- PCDH9 Depletion Reduces the Frequency of Leukemia-Induced CNS Pathology:
- PCDH9-deficient leukemia cells are tested for reduced capacity to give rise to CNS pathology (paralysis of the recipient mice).
- the specificity of PCDH9 KD is confirmed using a second independent shRNA construct for PCDH9.
- Cohorts of 5 C57BL/6 recipient mice are injected I.V. with 5 ⁇ 10 4 control or PCDH9 KD B-ALL cells. Recipient mice are observed daily for up to 6 weeks and euthanized upon developing signs of morbidity (e.g.
- PCDH9 in B-ALL leukemia cells is enforced in order to show if the expression is sufficient to promote CNS colonization and give rise to CNS pathology.
- the expression of PCDH9 is forced in the PCDH9-negative B-ALL cells that have a systemic phenotype.
- the time-course experiments discussed above are repeated to compare the capacity to colonize the CNS of control-transduced vs. PCDH9-transduced systemic B-ALL cells.
- the PCDH9-transduced systemic B-ALL cells give rise to CNS pathology compared to control-transduced B-ALL cells. It is expected that PCDH9 is sufficient to enable B-ALL cells to colonize the CNS and lead to CNS pathology.
- PCDH9 Regulates the Ability of Human ALL Cells to Colonize the CNS and Cause CNS Pathology:
- the proliferation rate of control and PCDH9 KD B-ALL cells, and control and PCDH9 KO NALM-6 cells is determined. If any differences are determined in disease progression or survival rates due to better control of CNS colonization or differences in initial engraftment, the level of engraftment of control vs. PCDH9-depleted B-ALL and NALM-6 cells within 24 hours of transfer is analyzed. If reduced numbers are detected of PCDH9-depleted vs. control cells in the blood or bone marrow of recipient mice within 24 hours, leukemia progression experiments transferring more PCDH9-depleted B-ALL or NALM-6 cells are repeated to obtain similar initial levels of leukemia engraftment.
- PCDH9 KD B-ALL cells due to possible selective pressure against PCDH9 KD, the expression level of PCDH9 in KD B-ALL cells recovered from the CNS and other tissues during leukemia progression is determined. If shRNA-mediated depletion of PCDH9 in B-ALL cells is lost over time in vivo, stable genetic PCDH9 KO B-ALL cells are established using CRISPR/Cas9 technology (as for the NALM-6 cells).
- CNS B-ALL cells transferred in immuno-competent non-irradiated mice typically results in overt leukemia and CNS pathology by 2-3 weeks post-transfer ( FIG. 1 and Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011); Williams, R. T., Roussel, M. F. & Sherr, C. J.
- dasatinib can slow leukemia progression in this mouse model of ALL it is still not able to effectively control CNS relapses (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011)), as is often the case in human clinical settings (Ottmann, O. et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.
- Dasatinib or vehicle-only treatment starts 2 or 6 days post B-ALL transfer.
- This delayed TKI treatment allows the development of different degrees of leukemia burden and possible CNS dissemination prior to treatment and mimics common clinical settings in which human patients present with significant disease burden at diagnosis.
- Dasatinib treatment is suspended after 4 weeks and the mice are continued to be monitored for up to 12 weeks to determine the frequency of leukemia relapse and CNS pathology. Recipient mice are observed daily and euthanized upon developing signs of morbidity, while CNS pathology is determined by the development of ascending paralysis, which in this setting is a sign of CNS colonization by leukemia cells. It is expected that PCDH9 depletion in combination with the TKI dasatinib prevents or reduces the frequency of leukemia relapse and improve survival.
- Alternative treatment conditions such as the following can be used: (1) different regimens of dasatinib (including starting treatment at different days post B-ALL transfer or prolonging the treatment window); and (2) adding a chemotherapy treatment such as dexamethasone (which has efficacy on this B-ALL cell line (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011))) to the dasatinib treatment.
- a chemotherapy treatment such as dexamethasone (which has efficacy on this B-ALL cell line (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-35
- PCDH9 blocking antibodies can have therapeutic efficacy in limiting leukemia CNS relapses without significant side-effects.
- targeted carriers such as B cell-directed antibodies or nanoparticles (Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010); Kim, S. S., Subramanya, S., Peer, D., Shimaoka, M. & Shankar, P. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol 721, 339-353 (2011); Peer, D., Park, E.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Gynecology & Obstetrics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
The present invention is related to novel methods for detecting and reducing cancer cell central nervous system colonization and methods of treating subjects having cancers that colonize in the central nervous system.
Description
- This application is a continuation of U.S. patent application Ser. No. 16/023,650, filed Jun. 29, 2018, which claims the benefit of priority under 35 U.S.C. § 119(e) to U.S. Provisional Patent Application No. 62/527,798, filed Jun. 30, 2017. The entire disclosures of U.S. Provisional Patent Application No. 62/527,798 and U.S. patent application Ser. No. 16/023,650 are incorporated herein by reference.
- Acute lymphoblastic Leukemia (ALL) is the most common type of childhood cancer with approximately 3000 newly diagnosed children each year in the USA. Current ALL therapies lead to high remission rates, but a significant number of patients relapse, with the relapsing leukemia often involving the Central Nervous System (CNS) (Pfeifer, H. et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical cancer research: an official journal of the American Association for Cancer Research 9, 4674-4681 (2003); Leis, J. F. et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & lymphoma 45, 695-698 (2004); Pui, C. H. & Thiel, E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Seminars in oncology 36, S2-S16 (2009)). The CNS acts as a ‘sanctuary’ site due to the presence of the blood brain barrier, which shields hematological cancer cells (such as leukemia cells and lymphoma cells) from treatments including tyrosine kinase inhibitors (TKIs) and chemotherapy (Aragon-Ching, J. B. & Zujewski, J. A. CNS metastasis: an old problem in a new guise. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 1644-1647 (2007); Wolff, N.C., Richardson, J. A., Egorin, M. & Ilaria, R. L., Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101, 5010-5013 (2003)). In the case of pediatric ALL only ˜5% of patients are initially diagnosed with CNS involvement; however, in the absence of CNS-directed treatments up to 40% of relapses can have CNS involvement (Pui, C. H. & Thiel, E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Seminars in oncology 36, S2-S16 (2009); Pui, C.-H. & Howard, S. C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. The Lancet Oncology 9, 257-268 (2008)). Even though in some cases the leukemia may already be present in the CNS below detection levels, in many cases the leukemia does not initially involve the CNS and can infiltrate the CNS during or after treatment. Additional treatments such as cranial irradiation, intrathecal administration of chemotherapy, or high dose chemotherapy have been used to reduce CNS relapses. With these CNS-specific treatments, the relapse rate can be lowered to 5-15% depending on the type and intensity of the treatments (Pui, C. H. & Thiel, E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Seminars in oncology 36, S2-S16 (2009); Pui, C.-H. & Howard, S. C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. The Lancet Oncology 9, 257-268 (2008)). However, short- and long-term side-effects, such as acute neurotoxicity, brain cancer, cognitive impairment and learning disabilities, can be very severe, particularly in children (Goshen, Y. et al. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatric blood & cancer 49, 294-297 (2007); Shuper, A. et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. Journal of
child neurology 15, 573-580 (2000); Moore, I. M. et al. Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Seminars inoncology nursing 16, 279-290; discussion 291-279 (2000)). - Thus, interventions that prevent or reverse hematological cancer cell (including leukemia and/or lymphoma cell) colonization of the CNS, and that can be combined with standard therapies, are novel tools to achieve full remission and improve long-term survival while reducing the severe side effects of CNS-directed treatments. There is an unmet need in the art to inhibit or reverse hematological cancer cell infiltration and colonization of the CNS, which can be present at diagnosis or happen over the course of anti-cancer treatments, in order to prevent relapses.
- One embodiment of the present invention is a method of treating cancer comprising administering to a subject in need thereof, a PCDH9 inhibitor. In one aspect, the cancer is leukemia or lymphoma. In still another aspect, the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
- Another embodiment of the present invention is a method to identify a subject at risk for leukemia cell colonization of the central nervous system (CNS) in a subject having leukemia, the method comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; and (c) identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control.
- Still another embodiment of the present invention is a method to reduce leukemia relapse in a subject, comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; (c) identifying the subject as at risk for leukemia relapse when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and (d) administering a PCDH9 inhibitor to the subject at risk.
- Another embodiment method to inhibit or reverse leukemia cell colonization of the CNS in a subject comprising (a) obtaining a blood sample from the subject; (b) detecting the expression level of PCDH9 in the sample; (c) identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and (d) administering a PCDH9 inhibitor to the subject.
- In any of the embodiments of the invention described above or elsewhere herein, the PCDH9 inhibitor is selected from the group consisting of an antibody, an antisense molecule, an siRNA molecule, an shRNA molecule, a receptor antagonist, a chemical entity, a nucleotide, a peptide, and a protein. In one aspect, the PCDH9 inhibitor is an PCDH9 antibody.
- In any of the embodiments of the invention described above or elsewhere herein, the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
-
FIGS. 1A and 1B . Differential phenotype of systemic B-cell acute lymphoblastic leukemia (B-ALL) and CNS B-ALL after in vivo transfer. 5×104 systemic B-ALL cells or CNS B-ALL cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology.FIG. 1A : Quantification of spleen weight at the time of death of recipient mice transferred with either CNS or systemic B-ALL cells. Black line indicates normal spleen weight.FIG. 1B : Quantification of CNS pathology in recipient mice transferred with CNS or systemic B-ALL cells. CNS pathology scoring: limp tail=1; limp tail and partial hind limb paralysis=2; limp tail and full hind limb paralysis=3; limp tail, complete hind leg and partial front leg paralysis=4. Data are pooled from 2 independent experiments with cohorts of 5 mice/group/experiment; error bars are SEM. -
FIG. 2 . PCDH9 is expressed in CNS leukemia cells but not systemic leukemia cells. Western blot analysis showing protein expression of PCDH9 in CNS B-ALL cells and lack of protein expression in systemic B-ALL cells. -
FIG. 3 . shRNA-mediated depletion of PCDH9 in CNS leukemia cells. Western blot analysis showing PCDH9 protein levels in CNS B-ALL cells transduced with either control shRNA or PCDH9 specific shRNA. -
FIGS. 4A and 4B . PCDH9 depletion in B-ALL cells greatly reduces the incidence and severity of CNS pathology. 5×104 control or PCDH9 KD (knock-down) CNS B-ALL cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology (as described inFIG. 1 ).FIG. 4A : Incidence of CNS pathology (p=0.0059).FIG. 4B : Quantification of severity of CNS pathology in recipient mice (p<0.0001). Data are pooled from 2 experiments with cohorts of 5 mice/group/experiment; error bars are SEM. -
FIG. 5 . PCDH9 is expressed in CNS B-ALL and in NALM-6 leukemia cells, but not systemic B-ALL cells. Western blot analysis showing protein expression of PCDH9 in CNS B-ALL and NALM-6 cells and lack of PCDH9 expression in systemic B-ALL cells. -
FIG. 6 . NALM-6 leukemia cells cause CNS pathology. 106 NALM-6 cells were transferred into severe combined immunodeficiency (SCID) recipient mice and scored daily for signs of leukemia and CNS pathology (as described in the text andFIG. 1 ). Quantification of severity of CNS pathology in recipient mice is shown. -
FIGS. 7A and 7B . PCDH9 KO (knock-out) in NALM-6 human leukemia cells greatly reduces the incidence and severity of CNS pathology. 5×104 control or PCDH9 KO NALM-6 cells were transferred into recipient mice and scored daily for signs of leukemia and CNS pathology.FIG. 7A : Incidence of CNS pathology (p=0.0059).FIG. 7B : Quantification of severity of CNS pathology in recipient mice (p<0.0001). Data are pooled from 3 experiments with cohorts of 4-5 mice/group/experiment; error bars are SEM. -
FIG. 8 . Higher PCDH9 mRNA expression in ALL patients with CNS relapse. Patients were stratified between individuals that experienced a CNS relapse and those who did not. Expression of PCDH9 mRNA detected by microarray is shown. Results show that higher PCDH9 expression correlates with CNS relapse in ALL patients. (p=0.037) -
FIG. 9 . shows a schematic for the setup for the long-term CNS colonization experiments discussed in the example section. - Acute lymphoblastic Leukemia (ALL) is the most common childhood cancer. Current therapies achieve high remission rates, but a significant number of patients relapse, often with Central Nervous System (CNS) involvement. Some CNS-directed treatments reduce CNS relapses but do not eliminate them. CNS-directed treatments such as cranial irradiation, intrathecal administration of chemotherapy, or high dose chemotherapy have been used to reduce CNS relapses. While the relapse rate has been significantly lowered, particularly with some high-intensity CNS-specific treatments, it has not been completely eliminated. Additionally, short- and long-term side-effects of CNS-directed treatments, such as acute neurotoxicity, brain cancer, cognitive impairment and learning disabilities, can be very severe particularly in children. Given these serious side-effects of current CNS-directed therapies in pediatric patients, inhibiting CNS colonization of leukemia cells is a valuable tool to reduce leukemia relapse, and improve survival and the quality of life in ALL patients by eliminating or reducing harmful CNS-directed therapies. Thus, methods to inhibit hematological cancer cell (including leukemia cells and lymphoma cells) colonization of the CNS to prevent relapses as disclosed herein fulfil an unmet need in the art.
- As disclosed herein, targets that enable leukemia cell colonization of the CNS have been identified by comparing leukemia cells that colonize the CNS versus leukemia cells that do not. This analysis identified Protocadherin-9 (PCDH9) as an ectopically expressed protein in CNS-colonizing leukemia cells. Based on this data, ectopic expression of PCDH9 can enable leukemia cells to colonize the CNS and give rise to CNS pathology and relapses. Thus, determining the efficacy of targeting PCDH9 to prevent or reverse leukemia cell colonization of the CNS and improve long-term survival by reducing relapses fulfills an unmet need in the art. Instead of using toxic treatments (such as intrathecal chemotherapy or radiation) to kill the leukemia cells in the CNS, the inventors demonstrate that inhibiting leukemia cell colonization of the CNS by inhibiting PCDH9 is an effective alternative. In addition to validating PCDH9 as a novel target for leukemia treatment, PCDH9 is a new diagnostic target that can establish the risk for CNS colonization in leukemia patients. This allows more effective stratification of CNS treatments, thereby reducing the use and intensity of deleterious CNS-directed therapies in lower risk patients including pediatric patients and thus improving their quality of life.
- To disseminate into the CNS, hematological cancer cells, such as leukemia cells or lymphoma cells, exit the blood circulation by migrating across blood vessel walls. Once in the CNS, these cells can establish a niche, escape systemic anti-cancer treatments, and eventually give rise to CNS relapses. The mechanisms of leukemia cell entry and colonization of the CNS are mostly unknown. Using mouse and human models of pre-B cell ALL (B-ALL), factors that allow leukemia cells to enter and colonize the CNS have been determined. The gene expression profile of two similarly derived mouse B-ALL cell lines that have very different CNS colonization phenotypes were compared. The first ALL cell line has a typical ‘systemic’ phenotype of bone marrow and spleen involvement, while the second B-ALL cell line rapidly disseminates to the CNS and gives rise to CNS pathology (ascending paralysis of the recipient mice) (
FIG. 1 —pathology scoring). RNA sequencing analysis revealed that the most differentially expressed gene was PCDH9. - PCDH9 is a transmembrane adhesion receptor of the protocadherin family, which is known to mediate calcium-dependent cell adhesion in neuronal tissues (Strehl, S., Glatt, K., Liu, Q. M., Glatt, H. & Lalande, M. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics 53, 81-89 (1998)). PCDH9 was virtually absent in the B-ALL line that exhibited a systemic phenotype, and was highly expressed (>27-fold) in the B-ALL line with the CNS colonization phenotype by both mRNA and Western Blot analysis (Table 1,
FIG. 2 ). PCDH9 is not expressed in normal leukocytes, but gene profiling of leukemia patient samples available in public databases shows that PCDH9 is ectopically expressed in various human leukemia samples. PCDH9 upregulation is also a poor prognostic factor in ALL (Silveira, V. S. et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia & lymphoma 54, 310-314 (2013)). PCDH9 depletion in leukemia cells greatly reduces their ability to give rise to CNS pathology (FIG. 4 ). Based on these data, ectopic expression of PCDH9 in leukemia cells is expected to enable leukemia cells to colonize the CNS and cause CNS pathology and relapses. Both the mouse ALL model just described and a human ALL xenograft model that also gives rise to CNS pathology in recipient mice can be used. -
TABLE 1 Comparison of PCDH9 mRNA expression in systemic vs. CNS leukemia cells ‘Systemic’ ‘CNS’ Normalized B-ALL B-ALL fold average average change Adjusted p (reads/106) (reads/106) (DSeq2) value PCDH-9 0.5 1965.3 27.48 1.5732 × 10−58 RNA sequencing was performed on the systemic and CNS B-ALL cells and analyzed using the D SEQ2 software. The most highly differentially expressed gene between the two leukemia lines was PCDH9. - The role of PCDH9 in allowing leukemia cells to enter and colonize the CNS, and give rise to CNS pathology and relapse is demonstrated herein. Furthermore, the results provide target validation for PCDH9 as a novel point of therapeutic intervention to inhibit leukemia cell colonization of the CNS and prevent relapses, including as part of combination therapies. Given the serious side-effects of CNS-directed therapies in children, inhibiting CNS colonization of leukemia cells is a valuable tool to improve current therapies by decreasing relapses following TKI and chemotherapy while also reducing the need or intensity of CNS-directed therapies.
- Leukemia as well as lymphoma cell colonization of the CNS can be particularly problematic since the CNS acts as ‘sanctuary’ site that protects leukemia or lymphoma cells from systemic treatments including chemotherapy and TKIs. This is mainly due to the reduced permeability of these drugs through the blood-brain barrier (Aragon-Ching, J. B. & Zujewski, J. A. CNS metastasis: an old problem in a new guise. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 1644-1647 (2007); Wolff, N.C., Richardson, J. A., Egorin, M. & Ilaria, R. L., Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101, 5010-5013 (2003)). Thus, therapeutics that inhibit leukemia and/or lymphoma cell colonization of the CNS can be used, in combination with systemic TKIs and/or chemotherapy, to more completely eradicate leukemia, to prevent relapses, and thereby increase long-term survival (typically defined as longer than 5 years from diagnosis in the case of ALL). Furthermore, reducing the need, frequency and intensity of treatments such as intrathecal chemotherapy can significantly reduce the deleterious side-effects of these therapies especially in children.
- Identification of PCDH9 as a novel target for prevention of leukemia CNS relapses: Relatively little is known about PCDH9. It belongs to the protocadherin family, a group of transmembrane proteins that mediate Ca′-dependent homotypic cell adhesion. PCDH9 is predominantly expressed in neuronal tissues and not normally expressed in leukocytes (Strehl, S., Glatt, K., Liu, Q. M., Glatt, H. & Lalande, M. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics 53, 81-89 (1998)). Ectopic expression of PCDH9 in human leukemia cells has been demonstrated by expression profiling, and includes but is not limited to human ALL. Furthermore, PCDH9 expression is a poor prognostic factor in ALL (Silveira, V. S. et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia & lymphoma 54, 310-314 (2013)). Ectopic expression of PCDH9 in leukemia cells is believed to allow them to adhere and interact with neuronal and/or glial cells enabling the leukemia cells to establish a niche in the CNS.
- Use of PCDH9 as a new diagnostic tool to predict the risk of CNS colonization: PCDH9 expression in leukemia cells is a factor that enables leukemia cells to colonize the CNS which allows for staining leukemia cells from a patient's blood sample for PCDH9 expression. This is a novel and greatly improved method to establish the risk for CNS colonization in leukemia patients. This enables more effective treatment stratification, thereby reducing the need and intensity of harmful CNS-directed therapies in lower risk patients.
- As discussed in the Example Section below, a mouse ALL model and a human ALL xenograft model that both give rise to CNS pathology are used to compare the ability of control ALL cells and PCDH9-depleted ALL cells to colonize the CNS and induce CNS pathology.
- PCDH9 expression in leukemia cells enables their establishment in the CNS. Using the CNS B-ALL cells in a mouse ALL transfer model, the ability of control shRNA and PCDH9 shRNA (PCDH9 KD) B-ALL cells to infiltrate the CNS and give rise to CNS pathology by time-course analysis is compared. Furthermore, using the human leukemia cell line NALM-6, knock-out (KO) of PCDH9 is shown to prevent CNS pathology by the human leukemia cells.
- An established mouse B-ALL model (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011); Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 6688-6693 (2006); Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes & development 21, 2283-2287 (2007)) is used in the example section herein. B-ALL are often initiated by a translocation between chromosomes 9 and 22, known as the Philadelphia chromosome, which results in the expression of the Bcr-Abl fusion protein. The presence of Bcr-Abl in leukemia cells typically carries a poor prognosis. Two mouse Bcr-Abl+Arf−/− B-ALL cell lines were derived by transducing bone marrow cells from Arf−/− (a tumor suppressor) C57BL/6 mice with p185Bcr-Abl and co-expressing either a GFP or luciferase as a marker (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011); Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 6688-6693 (2006)). While both B-ALL lines consistently induce lymphoid leukemia in healthy non-irradiated mice, these two B-ALL cell lines were determined to have very different in vivo phenotypes. The luciferase-expressing B-ALL cell line gives rise to a typical ‘systemic’ phenotype of bone marrow and spleen involvement, while the GFP-expressing B-ALL cell line infiltrates the CNS and gives rise to CNS pathology (paralysis of the recipient mice) in addition to systemic dissemination (
FIG. 1 ). - To extend these results to human ALL, a xenograft model with the human pre-B cell ALL cell line NALM-6, which carries a (5; 12) translocation was used. NALM-6 cells reliably engraft in SCID mice and have been used to test anti-leukemia experimental therapies in vivo (Jacoby, E., Chien, C. D. & Fry, T. J. Murine models of acute leukemia: important tools in current pediatric leukemia research. Frontiers in
oncology 4, 95 (2014)). Importantly, NALM-6 cells colonize the CNS at high frequency leading to CNS pathology in the recipient mice similarly to the mouse B-ALL model (Gunther, R. et al. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 85, 2537-2545 (1995)) (FIG. 6 ). - Differential expression of PCDH9 in systemic vs. CNS leukemia cells. To determine the molecular causes for such different in vivo phenotypes of the two mouse B-ALL cell lines used herein, RNA sequencing analysis was done to investigate differences in the expression profile between these B-ALL cell lines. Analysis revealed that the most differentially expressed gene was PCDH9, which was virtually absent from the systemic B-ALL cells and highly expressed in the CNS B-ALL cells (>27-fold based on the DSeq2 software analysis which normalizes fold changes based on expression levels and variance) (Table 1 and
FIG. 2 ). PCDH9 protein expression in NALM-6 ALL cells (FIG. 5 ) was also confirmed. - Depletion of PCDH9 in leukemia cells: PCDH9 expression was knocked-down (KD) using an shRNA-mediated approach (
FIG. 3 ). CNS B-ALL cells were transduced with control or PCDH9 inhibitory shRNA using retroviral vectors (pSiren-retroQ from Clontech), employing techniques similar to those used in other studies (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016); Jacobelli, J., Bennett, F. C., Pandurangi, P., Tooley, A. J. & Krummel, M. F. Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration. J Immunol 182, 2041-2050 (2009)). Before use, the transduced cells were sorted based on the DsRed fluorescent marker co-expressed by the shRNA encoding retroviral vectors. To completely eliminate PCDH9 expression in the human NALM-6 cells, PCDH9 was knocked out using CRISPR/Cas9 technology. - PCDH9 depletion significantly reduces CNS pathology caused by B-ALL transfer: In experiments the in vivo effects of transferring CNS B-ALL cells transduced with either control shRNA or PCDH9 shRNA was compared. Even though, in the absence of anti-leukemia treatments, mice transferred with control or PCDH9 KD B-ALL cells eventually succumbed to the leukemia, the data showed that PCDH9 depletion in leukemia cells strongly reduced their ability to cause CNS pathology in the recipient mice (
FIG. 4 ). - Knock-out of PCDH9 in human leukemia cells prevents CNS pathology: Control or PCDH9 KO human NALM-6 leukemia cells were transferred into SCID mice and leukemia progression and CNS pathology was monitored over time. These data showed that PCDH9 KO significantly reduced and almost eliminated the ability of NALM-6 cells to cause CNS pathology (
FIG. 7 ). Overall, these data support that PCDH9 expression enables leukemia cells to colonize the CNS and cause CNS pathology. - Higher PCDH9 expression correlates with CNS relapse in ALL patients: PCDH9 expression was analyzed from publicly available microarray gene expression data from a clinical study of ALL patients. Comparing patients with or without CNS relapse suggests that PCDH9 expression is significantly higher in the patients with CNS relapse (
FIG. 8 ). - By validating PCDH9 as a target in leukemia, new therapeutics to prevent or reverse leukemia colonization of the CNS ‘sanctuary’ site provide new treatment options for leukemia. Identifying PCDH9 as a protein that enables leukemia cells to colonize the CNS is used to develop new diagnostics to establish the risk for CNS dissemination in leukemia patients and more effectively stratify treatment.
- One embodiment of the present invention is a method of treating cancer comprising administering to a subject in need thereof, a PCDH9 inhibitor. In one aspect, the cancer is a hematological cancer including but not limited to leukemia and/or lymphoma. In one aspect, the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML). In one aspect of the invention described herein, the subject has been diagnosed as having cancer. In one aspect the cancer is a hematological cancer.
- Another embodiment of the present invention is the use of a PCDH9 inhibitor for treating cancer in a subject. In one aspect, the cancer is a hematological cancer including but not limited to leukemia and/or lymphoma. In one aspect, the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML). In one aspect of the invention described herein, the subject has been diagnosed as having cancer. In one aspect the cancer is a hematological cancer.
- One embodiment of the present invention is a method to identify a subject at risk for hematological cancer cell colonization of the central nervous system (CNS) in a subject having been diagnosed as having the hematological cancer. The method comprising obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; and identifying the subject as at risk for hematological cancer cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control. In one aspect, the hematological cancer is leukemia or lymphoma.
- Still another embodiment of the present invention is a method to reduce hematological cancer relapse in a subject. The method comprises obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; identifying the subject as at risk for hematological cancer relapse when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and administering a PCDH9 inhibitor to the subject at risk. In one aspect, the hematological cancer is leukemia or lymphoma.
- Another embodiment of the present invention is the use of a PCDH9 inhibitor to reduce hematological cancer relapse in as subject.
- Another embodiment of the present invention is a method to inhibit or reverse hematological cancer cell colonization of the CNS in a subject. The method comprises obtaining a sample from the subject; detecting the expression level of PCDH9 in the sample; identifying the subject as at risk for hematological cancer cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCDH9 from a control; and administering a PCDH9 inhibitor to the subject. In one aspect, the hematological cancer is leukemia or lymphoma.
- Another embodiment of the present invention is the use of a PCDH9 inhibitor to inhibit or reduce hematological cancer cell colonization of the CNS in a subject.
- A patient or subject sample can include any bodily fluid or tissue from a patient that may contain the RNA or protein encoded by the genes contemplated here. The term “sample” or “patient sample” or “subject sample” can be used generally to refer to a sample of any type which contains products that are to be evaluated by the present method, including but not limited to, a sample of isolated cells, a tissue sample and/or a bodily fluid sample. According to the present invention, a sample of isolated cells is a specimen of cells, typically in suspension or separated from connective tissue which may have connected the cells within a tissue in vivo, which have been collected from an organ, tissue or fluid by any suitable method which results in the collection of a suitable number of cells for evaluation by the method of the present invention.
- In some aspects, the sample can comprise blood. In still some aspects the sample can comprise whole blood, Peripheral Blood Mononuclear Cells (PBMCs), leukocytes, monocytes, lymphocytes, basophils, or eosinophils. In one aspect the blood sample comprises leukemia cells. In yet another aspect, the leukemia cells can be separated out from other cells and components in a blood sample.
- The PCDH9 inhibitor can be selected from an antibody, an antisense molecule, an siRNA molecule, an shRNA molecule, a receptor antagonist, a chemical entity, a nucleotide, a peptide, and a protein. In a preferred aspect, the PCDH9 inhibitor is a PCDH9 antibody.
- As used herein, the term “expression”, when used in connection with detecting the expression of a gene, can refer to detecting transcription of the gene (i.e., detecting mRNA levels) and/or to detecting translation of the gene (detecting the protein produced). To detect expression of a gene refers to the act of actively determining whether a gene is expressed or not. This can include determining whether the gene expression is upregulated (or increased) as compared to a control, downregulated as compared to a control, or unchanged as compared to a control or increased or decreased as compared to a reference or control level. Therefore, the step of detecting or determining expression does not require that expression of the gene actually is upregulated or downregulated or increased or decreased, but rather, can also include detecting or determining that the expression of the gene has not changed (i.e., detecting no expression of the gene or no change in expression of the gene).
- Expression of transcripts and/or proteins is measured by any of a variety of known methods in the art. For RNA expression, methods include but are not limited to: extraction of cellular mRNA and Northern blotting using labeled probes that hybridize to transcripts encoding all or part of the gene; amplification of mRNA using gene-specific primers, polymerase chain reaction (PCR), and reverse transcriptase-polymerase chain reaction (RT-PCR), quantitative PCR, and/or RNA Ampliseq, followed by quantitative detection of the product by any of a variety of means; multiplexed quantitative PCR enrichment of cDNA amplicons, followed by conversion of amplicons to sequence libraries and Next-generation based sequencing of libraries to generate digital count expression data; extraction of total RNA from the cells, which is then labeled and used to probe cDNAs or oligonucleotides encoding the gene on any of a variety of surfaces; in situ hybridization; and detection of a reporter gene.
- Methods to measure protein expression levels generally include, but are not limited to: mass spectrometry, Western blot, immunoblot, enzyme-linked immunosorbant assay (ELISA), radioimmunoassay (MA), immunoprecipitation, surface plasmon resonance, chemiluminescence, fluorescent polarization, phosphorescence, immunohistochemical analysis, matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry, microcytometry, microarray, microscopy, fluorescence activated cell sorting (FACS), and flow cytometry, as well as assays based on a property of the protein including but not limited to enzymatic activity or interaction with other protein partners. Binding assays are also well known in the art. For example, a BIAcore machine can be used to determine the binding constant of a complex between two proteins. The dissociation constant for the complex can be determined by monitoring changes in the refractive index with respect to time as buffer is passed over the chip (O'Shannessy et al., 1993, Anal. Biochem. 212:457; Schuster et al., 1993, Nature 365:343). Other suitable assays for measuring the binding of one protein to another include, for example, immunoassays such as enzyme linked immunoabsorbent assays (ELISA) and radioimmunoassays (MA); or determination of binding by monitoring the change in the spectroscopic or optical properties of the proteins through fluorescence, UV absorption, circular dichroism, or nuclear magnetic resonance (NMR).
- In one aspect, the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 is higher than the expression level of PCDH9 from a control. In one aspect, the expression can be at least about 5%, at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, higher than the expression level from the control. In still another aspect, the expression level can be at least about a 2 fold, at least about a 3 fold, at least about a 4 fold, at least about a 5 fold, at least about a 10-fold, at least about a 20 fold, at least about a 25 fold, at least about a 30 fold, at least about a 40 fold or at least about a 50 fold amount higher than the expression level from the control.
- As used herein, reference to a reference or control means a subject who is a relevant reference or control to the subject being evaluated by the methods of the present invention. Such a relevant reference or control includes but is not limited to a subject or group of subjects having a hematological cancer such as leukemia or lymphoma, but have not relapsed over a determined time period. The reference or control expression level, such as the level used to determine the threshold level, used in the comparison of the methods of the present invention can be determined from one or more relevant reference or control subjects.
- According to the methods of the present invention, a therapeutically effective amount of a PCDH9 inhibitor or a composition comprising a PCDH9 inhibitor that is administered to a subject, comprises an amount that is capable of inhibiting expression and/or activity of PCDH9 (mRNA and/or protein) without being toxic to the subject. An amount that is toxic to a subject comprises any amount that causes damage to the structure or function of a subject (i.e., poisonous). Further, the PCDH9 inhibitor can be used in combination with current ALL therapies. This approach is particularly valuable in reducing the need, duration, or intensity of CNS-directed therapies (intrathecal chemotherapy or cranial irradiation) which have deleterious side-effects, particularly in children.
- The invention also provides for a kit for determining expression level of PCDH9. The kit can comprise one or more components selected from an antibody, an antisense RNA molecule, and a molecular probe or tag, wherein in the component can detect the expression of PCDH9.
- In addition, according to the present invention, the composition as well as the kits of the present invention, can comprise a pharmaceutically acceptable excipient. According to the present invention, the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor, can be administered with a pharmaceutically acceptable carrier, which includes pharmaceutically acceptable excipients and/or delivery vehicles, for delivering the agent to a subject (e.g., a liposome delivery vehicle). As used herein, a pharmaceutically acceptable carrier refers to any substance suitable for delivering a therapeutic composition useful in the method of the present invention to a suitable in vivo or ex vivo site. Preferred pharmaceutically acceptable carriers are capable of maintaining the composition of the present invention in a form that, upon arrival of the composition to a target cell, the composition is capable of entering the cell and inhibiting PCDH9 (mRNA and/or protein) in the cell. Further, as PCDH9 is a surface molecule, an anti-PCDH9 antibody can also inhibit PCDH9 on the surface of the cells without having to enter to the cells. Suitable excipients of the present invention include excipients or formularies that transport or help transport, but do not specifically target a nucleic acid molecule to a cell (also referred to herein as non-targeting carriers). Examples of pharmaceutically acceptable excipients include, but are not limited to water, phosphate buffered saline, Ringer's solution, dextrose solution, serum-containing solutions, Hank's solution, other aqueous physiologically balanced solutions, oils, esters, glycols and combinations thereof. Aqueous carriers can contain suitable auxiliary substances required to approximate the physiological conditions of the recipient, for example, by enhancing chemical stability and isotonicity.
- Suitable auxiliary substances include, for example, sodium acetate, sodium chloride, sodium lactate, potassium chloride, calcium chloride, and other substances used to produce phosphate buffer, Tris buffer, and bicarbonate buffer. Auxiliary substances can also include preservatives, such as thimerosal, m- or o-cresol, formalin and benzol alcohol. Compositions of the present invention can be sterilized by conventional methods and/or lyophilized.
- Administration of a PCDH9 inhibitor or composition comprising a PCDH9 inhibitor can be systemic, mucosal and/or proximal to the location of the target site (e.g., near a site of a tumor). Suitable routes of administration will be apparent to those of skill in the art, depending on the type of cancer to be prevented or treated and/or the target cell population or tissue. Various acceptable methods of administration include, but are not limited to, intravenous administration, intraperitoneal administration, intramuscular administration, intranodal administration, intracoronary administration, intraarterial administration (e.g., into a carotid artery), subcutaneous administration, transdermal delivery, intratracheal administration, intraarticular administration, intraventricular administration, inhalation (e.g., aerosol), intracranial, intraspinal, intraocular, aural, intranasal, oral, pulmonary administration, impregnation of a catheter, and direct injection into a tissue. In one aspect, routes of administration include: intravenous, intraperitoneal, subcutaneous, intradermal, intranodal, intramuscular, transdermal, inhaled, intranasal, oral, intraocular, intraarticular, intracranial, and intraspinal. Parenteral delivery can include intradermal, intramuscular, intraperitoneal, intrapleural, intrapulmonary, intravenous, subcutaneous, atrial catheter and venal catheter routes. Aural delivery can include ear drops, intranasal delivery can include nose drops or intranasal injection, and intraocular delivery can include eye drops. Aerosol (inhalation) delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad. Sci. USA 189:11277-11281, 1992).
- In one aspect of the invention, one or more additional therapeutic agents or therapeutic protocols are administered or performed sequentially and/or concurrently with the administration of the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor, e.g., administration of chemotherapy, administration of radiation therapy, administration of a tyrosine kinase inhibitor (TKI), administration of an immunotherapy composition or immunotherapy including include the additional administration of other agents, such as cytokines, antibodies, or other agents.
- In one aspect, one or more therapies for cancer (including any therapies described herein or otherwise known in the art) can be administered or performed prior to, concurrently with, or after the administration of the PCDH9 inhibitor or composition comprising a PCDH9 inhibitor. In one embodiment, one or more therapies can be administered or performed in an alternating manner.
- According to the methods of the present invention, the subject can be any animal subject, and particularly, in any vertebrate mammal, including, but not limited to, primates, rodents, livestock or domestic pets. Preferred mammals for the methods of the present invention are humans.
- The following examples are provided for illustrative purposes and are not intended to limit the scope of the invention as claimed herein. Any variations which occur to the skilled artisan are intended to fall within the scope of the present invention. All references cited in the present application are incorporated by reference herein to the extent that there is no inconsistency with the present disclosure.
- PCDH9 Depletion Reduces B-ALL Leukemia Colonization of the CNS:
- Using a CNS B-ALL cell line, the ability of PCDH9-deficient leukemia cells to colonize the CNS in vivo is determined. For short-term assays (12, 24 and 48 hours post-transfer), 2×107 differentially fluorescently-labeled control and PCDH9 KD B-ALL cells, which express the congenic marker CD45.2, are intravenously (I. V.) co-transferred at a 1:1 ratio into CD45.1+C57BL/6 recipient mice. For long-term assays (every 3 days for up to 3 weeks) 5×104 control or PCDH9 KD B-ALL cells are transferred into separate cohorts of CD45.1+recipient mice then, every 3 days, 2 randomly selected surviving mice from each cohort are euthanized for analysis (
FIG. 9 ). By transferring 2×107 B-ALL cells, B-ALL cells infiltrating theCNS 24 hours post-transfer are detected and with 5×104 transferred B-ALL cells, disease progression over 2-3 weeks (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016)) is monitored. Mice given 5×104 transferred control B-ALL typically succumb to the leukemia within 21 days (Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016)). Using flow cytometry the number and ratio of control and PCDH9 KD leukemia cells present in the CNS (brain and spinal cord) is quantified in a similar manner to techniques described in Wigton, E. J., et al. (in Journal of leukocyte biology (2016)). For comparison and to demonstrate that PCDH9 depletion does not affect leukemia colonization of other tissues, the number and ratio of transferred control vs. PCDH9 KD leukemia cells in the blood and other typical leukemia dissemination sites including: bone marrow, spleen, lymph nodes, liver, and lungs are also quantified. It is expected that PCDH9 depletion reduces B-ALL cell colonization of the CNS and other tissues over time. - PCDH9 Depletion Reduces the Frequency of Leukemia-Induced CNS Pathology:
- Following experiments with the CNS B-ALL cells as shown in
FIG. 4 , PCDH9-deficient leukemia cells are tested for reduced capacity to give rise to CNS pathology (paralysis of the recipient mice). The specificity of PCDH9 KD is confirmed using a second independent shRNA construct for PCDH9. Cohorts of 5 C57BL/6 recipient mice are injected I.V. with 5×104 control or PCDH9 KD B-ALL cells. Recipient mice are observed daily for up to 6 weeks and euthanized upon developing signs of morbidity (e.g. >20% weight loss, or a combination of 15-20% weight loss and any of the following: hunched posture, reduced activity, dehydration, respiratory distress, poor mobility, or ascending paralysis of the recipient mice—a sign of CNS infiltration by the leukemia). CNS pathology is scored on a scale of 0 to 5, and mice may be given in between scores (e.g. 0.5, 1.5, etc.) when the clinical picture lies between two defined scores. Scoring is as follows: normal motor functions of the mouse=0; limp tail=1; limp tail and partial hind limb paralysis=2; limp tail and full hind limb paralysis=3; limp tail, complete hind leg and partial front leg paralysis=4; complete paralysis=5. Mice typically do not score higher than 3 and any mouse with a score of 4 or higher will be immediately euthanized. It is expected that PCDH9 deficiency prevents or reduces the incidence and severity of leukemia-induced CNS pathology. - Expression of PCDH9 Sufficient to Promote Leukemia CNS Colonization and Pathology:
- Expression of PCDH9 in B-ALL leukemia cells is enforced in order to show if the expression is sufficient to promote CNS colonization and give rise to CNS pathology. Using retroviral transduction, the expression of PCDH9 is forced in the PCDH9-negative B-ALL cells that have a systemic phenotype. The time-course experiments discussed above are repeated to compare the capacity to colonize the CNS of control-transduced vs. PCDH9-transduced systemic B-ALL cells. The PCDH9-transduced systemic B-ALL cells give rise to CNS pathology compared to control-transduced B-ALL cells. It is expected that PCDH9 is sufficient to enable B-ALL cells to colonize the CNS and lead to CNS pathology.
- PCDH9 Regulates the Ability of Human ALL Cells to Colonize the CNS and Cause CNS Pathology:
- This examples discusses if PCDH9 depletion inhibits the capacity of human B-ALL cells to colonize the CNS and give rise to CNS pathology. For these experiments, the human B-ALL cell line NALM-6 is used which gives rise to CNS pathology in a xenograft model22. 5×106 control or PCDH9 KO NALM-6 cells is I.V. transferred into cohorts of SCID mice. The ability of PCDH9-deficient NALM-6 cells (identified by staining for human CD19 and CD22) to colonize the CNS in vivo is determined using a time-course analysis every 7 days for 6 weeks and to cause CNS pathology over 12 weeks. It is expected that PCDH9 also plays a key role in enabling human ALL cells to colonize the CNS and cause CNS pathology.
- The proliferation rate of control and PCDH9 KD B-ALL cells, and control and PCDH9 KO NALM-6 cells is determined. If any differences are determined in disease progression or survival rates due to better control of CNS colonization or differences in initial engraftment, the level of engraftment of control vs. PCDH9-depleted B-ALL and NALM-6 cells within 24 hours of transfer is analyzed. If reduced numbers are detected of PCDH9-depleted vs. control cells in the blood or bone marrow of recipient mice within 24 hours, leukemia progression experiments transferring more PCDH9-depleted B-ALL or NALM-6 cells are repeated to obtain similar initial levels of leukemia engraftment. Additionally, due to possible selective pressure against PCDH9 KD, the expression level of PCDH9 in KD B-ALL cells recovered from the CNS and other tissues during leukemia progression is determined. If shRNA-mediated depletion of PCDH9 in B-ALL cells is lost over time in vivo, stable genetic PCDH9 KO B-ALL cells are established using CRISPR/Cas9 technology (as for the NALM-6 cells).
- PCDH9 KD with TKI Treatment Improve Post-Treatment Survival in a B-ALL Transfer Model:
- In this leukemia mouse model, in the absence of anti-leukemia treatment, CNS B-ALL cells transferred in immuno-competent non-irradiated mice typically results in overt leukemia and CNS pathology by 2-3 weeks post-transfer (
FIG. 1 and Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011); Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 6688-6693 (2006)). Cohorts of 5 C57BL/6 mice are injected I.V. with 5×104 control or PCDH9 KD B-ALL cells. Mouse cohorts are treated daily with vehicle or the TKI dasatinib (a second-generation Bcr-Abl inhibitor) typically used for treatment of Bcr-Abl+ALL patients (Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. The New England journal of medicine 354, 166-178 (2006)). Although dasatinib can slow leukemia progression in this mouse model of ALL it is still not able to effectively control CNS relapses (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011)), as is often the case in human clinical settings (Ottmann, O. et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of aphase 2 study. Blood 110, 2309-2315 (2007)). Dasatinib or vehicle-only treatment starts 2 or 6 days post B-ALL transfer. This delayed TKI treatment allows the development of different degrees of leukemia burden and possible CNS dissemination prior to treatment and mimics common clinical settings in which human patients present with significant disease burden at diagnosis. Dasatinib treatment is suspended after 4 weeks and the mice are continued to be monitored for up to 12 weeks to determine the frequency of leukemia relapse and CNS pathology. Recipient mice are observed daily and euthanized upon developing signs of morbidity, while CNS pathology is determined by the development of ascending paralysis, which in this setting is a sign of CNS colonization by leukemia cells. It is expected that PCDH9 depletion in combination with the TKI dasatinib prevents or reduces the frequency of leukemia relapse and improve survival. - The Combination of PCDH9 Depletion and Anti-Leukemia Treatment in a Human Xenograft Leukemia Model Prevent Relapses and Improve Survival:
- Translatability of PCDH9 inhibition in the context of human leukemia, is determined using a xenograft leukemia model with human NALM-6 B-ALL cells, which give rise to CNS pathology (as described above). 5×106 control or PCDH9 KO NALM-6 cells is I.V. transferred into cohorts of 5 SCID mice and then treated daily for 4 weeks with vehicle or dexamethasone (a glucocorticoid chemotherapy agent used in the clinic that has efficacy on NALM-6 cells; administered in drinking water at 6 mg/L). Dexamethasone treatment is suspended after 4 weeks and the mice continue to be monitored for up to 12 weeks to determine the frequency of leukemia relapse and CNS pathology. It is expected that PCDH9 depletion in combination with chemotherapy prevents or reduces the frequency of leukemia relapse improving survival in human leukemia xenograft model.
- Alternative treatment conditions such as the following can be used: (1) different regimens of dasatinib (including starting treatment at different days post B-ALL transfer or prolonging the treatment window); and (2) adding a chemotherapy treatment such as dexamethasone (which has efficacy on this B-ALL cell line (Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011))) to the dasatinib treatment. Similarly, in the case of the NALM-6 xenograft model alternative chemotherapy regimens and treatments can be used. NALM-6 cells are not Bcr-Abl+therefore dasatinib TKI treatment is not a viable option.
- PCDH9 blocking antibodies can have therapeutic efficacy in limiting leukemia CNS relapses without significant side-effects. To prevent leukemia relapses in the CNS, particularly if PCDH9 antibodies have undesirable side-effects, targeted carriers (such as B cell-directed antibodies or nanoparticles (Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010); Kim, S. S., Subramanya, S., Peer, D., Shimaoka, M. & Shankar, P. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol 721, 339-353 (2011); Peer, D., Park, E. J., Morishita, Y., Carman, C. V. & Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008)) loaded with PCDH9-specific interfering-RNA for delivery to leukemia cells are used. This allows selective targeting of leukemia cells, or only a particular leukocyte subset (such as B cells), thus minimizing possible unwanted effects of more generalized PCDH9 inhibition.
- Primary human leukemia xenografts into NSG (NOD SCID Gamma) mice are analyzed to confirm the efficacy of PCDH9 KD on a range of primary leukemias derived from pediatric patients. It is expected that PCDH9 depletion in primary human leukemia cells will also prevent or reduce CNS colonization in these xenograft models.
- In the examples above, focus is on models of ALL, although the data obtained is relevant to any leukemia that uses ectopic PCDH9 expression as a means to invade and colonize the CNS. This further broadens the benefits of PCDH9 inhibition, including in combination therapies.
- While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention.
-
- 1. Pfeifer, H. et al. Risk and prognosis of central nervous system leukemia in patients with Philadelphia chromosome-positive acute leukemias treated with imatinib mesylate. Clinical cancer research: an official journal of the American Association for Cancer Research 9, 4674-4681 (2003).
- 2. Leis, J. F. et al. Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leukemia & lymphoma 45, 695-698 (2004).
- 3. Pui, C. H. & Thiel, E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Seminars in oncology 36, S2-S16 (2009).
- 4. Aragon-Ching, J. B. & Zujewski, J. A. CNS metastasis: an old problem in a new guise. Clinical cancer research: an official journal of the American Association for Cancer Research 13, 1644-1647 (2007).
- 5. Wolff, N.C., Richardson, J. A., Egorin, M. & Ilaria, R. L., Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia. Blood 101, 5010-5013 (2003).
- 6. Pui, C.-H. & Howard, S. C. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. The Lancet Oncology 9, 257-268 (2008).
- 7. Espy, K. A. et al. Chemotherapeutic CNS prophylaxis and neuropsychologic change in children with acute lymphoblastic leukemia: a prospective study. Journal of pediatric psychology 26, 1-9 (2001).
- 8. Goshen, Y. et al. High incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia. Pediatric blood & cancer 49, 294-297 (2007).
- 9. Shuper, A. et al. Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity. Journal of
child neurology 15, 573-580 (2000). - 10. Strehl, S., Glatt, K., Liu, Q. M., Glatt, H. & Lalande, M. Characterization of two novel protocadherins (PCDH8 and PCDH9) localized on human chromosome 13 and mouse chromosome 14. Genomics 53, 81-89 (1998).
- 11. Silveira, V. S. et al. Gene expression pattern contributing to prognostic factors in childhood acute lymphoblastic leukemia. Leukemia & lymphoma 54, 310-314 (2013).
- 12. Moore, I. M. et al. Cognitive consequences and central nervous system injury following treatment for childhood leukemia. Seminars in
oncology nursing 16, 279-290; discussion 291-279 (2000). - 13. Wigton, E. J., Thompson, S. B., Long, R. A. & Jacobelli, J. Myosin-IIA regulates leukemia engraftment and brain infiltration in a mouse model of acute lymphoblastic leukemia. Journal of leukocyte biology (2016).
- 14. Jacobelli, J., Estin Matthews, M., Chen, S. & Krummel, M. F. Activated T Cell Trans-Endothelial Migration Relies on Myosin-IIA Contractility for Squeezing the Cell Nucleus through Endothelial Cell Barriers.
PloS one 8, e75151 (2013). - 15. Jacobelli, J. et al. Confinement-optimized three-dimensional T cell amoeboid motility is modulated via myosin IIA-regulated adhesions. Nature immunology 11, 953-961 (2010).
- 16. Wang, C. et al. Downregulation of PCDH9 predicts prognosis for patients with glioma. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 19, 541-545 (2012).
- 17. Wang, C. et al. Characterizing the role of PCDH9 in the regulation of glioma cell apoptosis and invasion. Journal of molecular neuroscience: MN 52, 250-260 (2014).
- 18. Boulos, N. et al. Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 117, 3585-3595 (2011).
- 19. Williams, R. T., Roussel, M. F. & Sherr, C. J. Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America 103, 6688-6693 (2006).
- 20. Williams, R. T., den Besten, W. & Sherr, C. J. Cytokine-dependent imatinib resistance in mouse BCR-ABL+, Arf-null lymphoblastic leukemia. Genes & development 21, 2283-2287 (2007).
- 21. Jacoby, E., Chien, C. D. & Fry, T. J. Murine models of acute leukemia: important tools in current pediatric leukemia research. Frontiers in
oncology 4, 95 (2014). - 22. Gunther, R. et al. Biotherapy for xenografted human central nervous system leukemia in mice with severe combined immunodeficiency using B43 (anti-CD19)-pokeweed antiviral protein immunotoxin. Blood 85, 2537-2545 (1995).
- 23. Jacobelli, J., Bennett, F. C., Pandurangi, P., Tooley, A. J. & Krummel, M. F. Myosin-IIA and ICAM-1 regulate the interchange between two distinct modes of T cell migration. J Immunol 182, 2041-2050 (2009).
- 24. Pui, C. H. & Evans, W. E. Treatment of acute lymphoblastic leukemia. The New England journal of medicine 354, 166-178 (2006).
- 25. Ottmann, O. et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a
phase 2 study. Blood 110, 2309-2315 (2007). - 26. Hu, Y. et al. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+leukemia in mice. Proceedings of the National Academy of Sciences of the United States of America 103, 16870-16875 (2006).
- 27. Davis, M. E. et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464, 1067-1070 (2010).
- 28. Kim, S. S., Subramanya, S., Peer, D., Shimaoka, M. & Shankar, P. Antibody-mediated delivery of siRNAs for anti-HIV therapy. Methods Mol Biol 721, 339-353 (2011).
- 29. Peer, D., Park, E. J., Morishita, Y., Carman, C. V. & Shimaoka, M. Systemic leukocyte-directed siRNA delivery revealing cyclin D1 as an anti-inflammatory target. Science 319, 627-630 (2008).
Claims (20)
1. A method of treating cancer comprising administering to a subject in need thereof, a Protocadherin-9 (PCDH9) inhibitor, wherein the cancer is leukemia or lymphoma and wherein the PCDH9 inhibitor is a PCDH9 antibody.
2. (canceled)
3. The method of claim 2 , wherein the leukemia is Acute Lymphoblastic Leukemia (ALL) or Acute Myeloid Leukemia (AML).
4. (canceled)
5. (canceled)
6. The method of claim 1 , wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
7. The method of claim 1 , wherein the subject is human.
8. A method to identify a subject at risk for leukemia cell colonization of the central nervous system (CNS) in a subject having leukemia, the method comprising:
a. obtaining a blood sample from the subject;
b. detecting the expression level of PCDH9 in the sample; and
c. identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and
d. administering a PCDH9 inhibitor to the subject identified as being at risk, wherein the PCDH9 inhibitor is a PCDH9 antibody.
9. (canceled)
10. (canceled)
11. (canceled)
12. The method of claim 10 , wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
13. A method to reduce leukemia relapse in a subject, comprising:
a. obtaining a blood sample from the subject;
b. detecting the expression level of PCDH9 in the sample;
c. identifying the subject as at risk for leukemia relapse when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and
d. administering a PCDH9 inhibitor to the subject at risk, wherein the PCDH9 inhibitor is a PCDH9 antibody.
14. (canceled)
15. (canceled)
16. The method of claim 13 , wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
17. A method to inhibit or reverse leukemia cell colonization of the CNS in a subject comprising:
a. obtaining a blood sample from the subject;
b. detecting the expression level of PCDH9 in the sample;
c. identifying the subject as at risk for leukemia cell colonization of the CNS when either the presence of PCDH9 expression is detected above a control threshold level or the expression level of PCDH9 in the sample is higher than the expression level of PCHD9 from a control; and
d. administering a PCDH9 inhibitor to the subject, wherein the PCDH9 inhibitor is a PCDH9 antibody.
18. (canceled)
19. (canceled)
20. The method of claim 17 , wherein the subject is further administered a systemic therapy selected from the group consisting of chemotherapy, radiation, and tyrosine kinase inhibitor (TKI) therapy.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/224,431 US20220057404A1 (en) | 2017-06-30 | 2021-04-07 | Methods of detecting and reducing cancer cell central nervous system colonization |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762527798P | 2017-06-30 | 2017-06-30 | |
US16/023,650 US11002740B2 (en) | 2017-06-30 | 2018-06-29 | Methods of detecting and reducing cancer cell central nervous system colonization |
US17/224,431 US20220057404A1 (en) | 2017-06-30 | 2021-04-07 | Methods of detecting and reducing cancer cell central nervous system colonization |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,650 Continuation US11002740B2 (en) | 2017-06-30 | 2018-06-29 | Methods of detecting and reducing cancer cell central nervous system colonization |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220057404A1 true US20220057404A1 (en) | 2022-02-24 |
Family
ID=64738666
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,650 Active 2039-02-16 US11002740B2 (en) | 2017-06-30 | 2018-06-29 | Methods of detecting and reducing cancer cell central nervous system colonization |
US17/224,431 Abandoned US20220057404A1 (en) | 2017-06-30 | 2021-04-07 | Methods of detecting and reducing cancer cell central nervous system colonization |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/023,650 Active 2039-02-16 US11002740B2 (en) | 2017-06-30 | 2018-06-29 | Methods of detecting and reducing cancer cell central nervous system colonization |
Country Status (2)
Country | Link |
---|---|
US (2) | US11002740B2 (en) |
WO (1) | WO2019006354A1 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095764A1 (en) * | 2004-06-17 | 2008-04-24 | The Trustees Of Columbia University In The City Of New York | Use of genetically-and epigenetically-altered protocadherins in methods of diagnosing, prognosing, and treating cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040018513A1 (en) * | 2002-03-22 | 2004-01-29 | Downing James R | Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling |
WO2004110345A2 (en) | 2002-10-29 | 2004-12-23 | Pharmacia Corporation | Differentially expressed genes involved in cancer, the polypeptides encoded thereby, and methods of using the same |
WO2012134813A1 (en) | 2011-03-31 | 2012-10-04 | St. Jude Children's Research Hospital | Methods and compositions for identifying minimal residual disease in acute lymphoblastic leukemia |
US9417244B2 (en) * | 2011-09-28 | 2016-08-16 | The General Hospital Corporation | Cadherins as cancer biomarkers |
US20200063210A1 (en) * | 2016-12-05 | 2020-02-27 | Wake Forest University Health Sciences | Gene Expression Signatures Associated with Patient Response to Acute Myeloid Leukemia Treatment and Use Thereof for Predicting Response to Therapy |
-
2018
- 2018-06-29 US US16/023,650 patent/US11002740B2/en active Active
- 2018-06-29 WO PCT/US2018/040375 patent/WO2019006354A1/en active Application Filing
-
2021
- 2021-04-07 US US17/224,431 patent/US20220057404A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080095764A1 (en) * | 2004-06-17 | 2008-04-24 | The Trustees Of Columbia University In The City Of New York | Use of genetically-and epigenetically-altered protocadherins in methods of diagnosing, prognosing, and treating cancer |
Non-Patent Citations (2)
Title |
---|
Jiang et al. (J. Biol. Chem., 280: 4656-4662, 2005, in IDS from 08/31/2021) * |
Stancovski et al. (PNAS, 88: 8691-8695, 1991, in IDS from 08/31/2021) * |
Also Published As
Publication number | Publication date |
---|---|
US11002740B2 (en) | 2021-05-11 |
WO2019006354A1 (en) | 2019-01-03 |
US20190004053A1 (en) | 2019-01-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bywater et al. | Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53 | |
JP6527565B2 (en) | Method for treating hair loss disorders | |
Mao et al. | A CDC20-APC/SOX2 signaling axis regulates human glioblastoma stem-like cells | |
Reavie et al. | Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression | |
Shao et al. | Deletion of proapoptotic Puma selectively protects hematopoietic stem and progenitor cells against high-dose radiation | |
US11971402B2 (en) | Methods and reagents for determination and treatment of organotropic metastasis | |
ES2900301T3 (en) | Biomarkers associated with BRM inhibition | |
US9642821B2 (en) | MiR-182 in the diagnosis and treatment of cancer | |
Puram et al. | STAT3-iNOS signaling mediates EGFRvIII-induced glial proliferation and transformation | |
Penning et al. | Novel BRAF gene fusions and activating point mutations in spindle cell sarcomas with histologic overlap with infantile fibrosarcoma | |
Zhang et al. | Critical role for GAB2 in neuroblastoma pathogenesis through the promotion of SHP2/MYCN cooperation | |
AU2014348291A9 (en) | Compositions and methods of using transposons | |
US11248252B2 (en) | Treatment and diagnosis of immune disorders | |
WO2014199377A1 (en) | Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression | |
JP5696320B2 (en) | A method for assisting prognosis of ovarian cancer using the copy number of α-actinin-4 gene as an index and a kit for prognosis | |
Lee et al. | Genome‐scale CRISPR screening identifies cell cycle and protein ubiquitination processes as druggable targets for erlotinib‐resistant lung cancer | |
US9187787B2 (en) | Method of diagnosing and treating cancer | |
US20220057404A1 (en) | Methods of detecting and reducing cancer cell central nervous system colonization | |
US10865415B2 (en) | Prevention, diagnosis and treatment of cancer overexpressing GPR160 | |
Sun et al. | Glioblastoma cellular MAP4K1 facilitates tumor growth and disrupts T effector cell infiltration | |
WO2016098873A1 (en) | Method for determining risk of developing primary central nervous system lymphoma, and composition for treating primary central nervous system lymphoma | |
US20170027955A1 (en) | Expression levels of bcl-xl, bcl2, bcl-w, and bad and cancer therapies | |
US20220220565A1 (en) | Methods and compositions for treating melanoma | |
WO2022270621A1 (en) | Novel therapeutic agent that suppresses metastasis and proliferation of osteosarcoma and glioma | |
Saleh | Novel Insights Into The Contribution Of Cellular Senescence To Cancer Therapy: Reversibility, Dormancy And Senolysis. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: NATIONAL JEWISH HEALTH, COLORADO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JACOBELLI, JORDAN;THOMPSON, SCOTT;CHUNG, JEFFREY;SIGNING DATES FROM 20170720 TO 20180628;REEL/FRAME:056003/0724 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |